Akshata Sharma
Share
As per recent reports, Namita Thapar's current investment in Emcure Pharmaceuticals Limited grew by a massive 38,200% to ₹671 crore - following the company's 31% listing premium on the NSE. Let's take a closer look at her iconic entrepreneurial and investment journey
Emcure Pharmaceuticals' ₹1,952 Cr IPO received 67.87 times subscription on the final day of the offer on Friday.
In 2007, after her MBA and a successful stint at a US medical device company - Namita returned to India to join her family business, Emcure, as the CFO and was soon appointed as the Executive Director.
In 2021, the company reported a profit of Rs 418 crore on a revenue of Rs 6091 crore!
In addition to Emcure, Thapar leads Incredible Ventures Ltd, an education company that teaches entrepreneurship to 11 to 18-year-olds.
--Advertisement--
